Existing IND Sample Clauses

Existing IND. As of the Effective Date, FivePrime holds an IND for FP-1039 in the U.S. with the IND No. *** (FP-1039) (the “Existing IND”), under which it is conducting the FivePrime-Conducted Trials. As of the Effective Date, FivePrime plans to complete the FP-1039 Phase 1 Trial, and to continue conducting the FP-1039 Endometrial Trial (FP-1039-002) in the U.S. under the same IND and in other countries under INDs to be filed in such other countries that are substantially foreign equivalents of the Existing IND (such future INDs, the “Endometrial Foreign INDs”).
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Existing IND. OGX shall hold, under the direction and control of the JSC, the U.S. IND for Licensed Products that exists as of the Effective Date (“Existing IND”), until such time as either Teva or OGX requests such Existing IND to be transferred to Teva, at which time OGX shall promptly transfer the Existing IND to Teva.
Sample 1
Existing IND. Vical has sufficient legal and/or beneficial title and ownership in the Existing IND sufficient to transfer such Existing IND to Astellas in accordance with Section 4.1; no Regulatory Authority has, to Vical’s knowledge, commenced or threatened to initiate any action or proceeding to refuse to file, reject, not approve, or withdraw the Existing IND, nor has Vical received any notice to such effect; and to Vical’s knowledge, Vical is not in violation of any applicable laws that could reasonably be expected to form the basis for such an action.
Sample 1
Existing IND. Array shall retain ownership, and remain the sponsor, of the Initial IND until the last patient visit in the 403 MAD and the 403 Bioequivalence Trial. Array shall notify Amgen within fifteen (15) days after the occurrence of the last patient visit in the 403 MAD and the 403 Bioequivalence Trial. Upon the request of Amgen following such event, Array shall transfer the Initial IND to Amgen or, if directed by Amgen, close or inactivate the Initial IND as soon as reasonably practicable. Array shall complete all relevant clinical trial and Initial IND administrative activities for the 403 MAD and the 403 Bioequivalence Trials and shall promptly, on a regular basis and as requested by Amgen, share all clinical trial data with Amgen. Amgen shall be responsible for the preparation and filing of all subsequent IND(s) or other regulatory filings with respect to any clinical development for ARRY-403 other than the 403 SAD, 403 MAD and 403 Bioequivalence Trial.
Sample 1

Related to Existing IND

  • Existing Indebtedness (a) Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Indebtedness of the Company as of March 31, 2014 (including a description of the obligors and obligees, principal amount outstanding and collateral therefor, if any, and Guaranty thereof, if any), since which date there has been no Material change in the amounts, interest rates, sinking funds, installment payments or maturities of the Indebtedness of the Company. The Company is not in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of the Company and no event or condition exists with respect to any Indebtedness of the Company the outstanding principal amount of which exceeds $5,000,000 that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Indebtedness to become due and payable before its stated maturity or before its regularly scheduled dates of payment.

  • Existing Lock-Up Agreements Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there are no existing agreements between the Company and its security holders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company’s securities. The Company will direct the transfer agent to place stop transfer restrictions upon the securities of the Company that are bound by such “lock-up” agreements for the duration of the periods contemplated therein.

  • Existing Indebtedness; Future Liens (a) Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Indebtedness of the Company and its Subsidiaries as of the dates specified in such Schedule (and specifying, as to each such Indebtedness, the collateral, if any, securing such Indebtedness), since which date there has been no Material change in the amounts, interest rates, sinking funds, installment payments or maturities of the Indebtedness of the Company or its Subsidiaries. Neither the Company nor any Subsidiary is in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of the Company or such Subsidiary and no event or condition exists with respect to any Indebtedness of the Company or any Subsidiary that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Indebtedness to become due and payable before its stated maturity or before its regularly scheduled dates of payment.

  • DESCRIPTION OF EXISTING INDEBTEDNESS AND OBLIGATIONS Among other indebtedness and obligations which may be owing by Borrower to Bank, Borrower is indebted to Bank pursuant to a loan arrangement dated as of June 11, 2003, evidenced by, among other documents, a certain Loan and Security Agreement dated as of June 11, 2003 between Borrower and Bank, as amended from time to time (as amended, the "Loan Agreement"). Capitalized terms used but not otherwise defined herein shall have the same meaning as in the Loan Agreement.

  • Existing Agreements The Executive represents to the Company that he is not subject or a party to any employment or consulting agreement, non-competition covenant or other agreement, covenant or understanding which might prohibit him from executing this Agreement or limit his ability to fulfill his responsibilities hereunder.

  • Existing Agreement Except as expressly amended herein, the Credit Agreement shall remain in full force and effect, and in all other respects is affirmed.

  • Prior Agreements; Amendments This Agreement supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof. This Agreement may be amended only by a written instrument duly executed by the parties hereto or their respective successors or assigns.

  • Existing Arrangements From and after the Effective Time, the Surviving Corporation will (and Parent will cause the Surviving Corporation to) honor all of the Employee Plans and compensation and severance arrangements in accordance with their terms as in effect immediately prior to the Effective Time. Notwithstanding the foregoing, nothing will prohibit the Surviving Corporation from in any way amending, modifying or terminating any such Employee Plans or compensation or severance arrangements in accordance with their terms or if otherwise required pursuant to applicable law.

  • Parties to Lock-Up Agreements The Company has furnished to the Underwriters a letter agreement in the form attached hereto as Exhibit A (the “Lock-up Agreement”) from each of the persons listed on Exhibit B. Such Exhibit B lists under an appropriate caption the directors and executive officers of the Company. If any additional persons shall become directors or executive officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement.

  • Existing Agreements Superseded In the case of each Fund, to the extent that this Agreement provides for expense limit arrangements for the same classes of the Fund to which an existing expense limit agreement relates (each an “Existing Agreement”), this Agreement shall supersede and replace the Existing Agreement. In witness whereof, the parties hereto have caused this Agreement to be signed as of the 1st day of December, 2022. Each of the Funds Listed on Annex A. By: /s/ Xxxx X. Xxxxx Name: Xxxx X. Xxxxx Title: President AMUNDI ASSET MANAGEMENT US, INC. By: /s/ Xxxxx X. Xxxxxxx Name: Xxxxx X. Xxxxxxx Title: Chief Financial Officer Annex A Amundi Climate Transition Core Bond Fund (a series of Pioneer Series Trust IV) Pioneer AMT-Free Municipal Fund (a series of Pioneer Series Trust II) Pioneer Balanced ESG Fund (a series of Pioneer Series Trust IV) Pioneer CAT Bond Fund (a series of Pioneer Series Trust VII) Pioneer Corporate High Yield Fund (a series of Pioneer Series Trust X) Pioneer Disciplined Value Fund (a series of Pioneer Series Trust III) Pioneer Emerging Markets Equity Fund (a series of Pioneer Series Trust XIV) Pioneer Flexible Opportunities Fund (a series of Pioneer Series Trust VI) Pioneer Floating Rate Fund (a series of Pioneer Series Trust VI) Pioneer Fund Pioneer Fundamental Growth Fund (a series of Pioneer Series Trust X) Pioneer Global Sustainable Equity Fund (formerly, Pioneer Global Equity Fund) (a series of Pioneer Series Trust V) Pioneer Global High Yield Fund (a series of Pioneer Series Trust VII) Pioneer Global Sustainable Growth Fund (a series of Pioneer Series Trust XIV) Pioneer Global Sustainable Value Fund (a series of Pioneer Series Trust XIV) Pioneer High Income Municipal Fund (a series of Pioneer Series Trust V) Pioneer High Yield Fund Pioneer International Equity Fund (a series of Pioneer Series Trust VIII) Pioneer Intrinsic Value Fund (a series of Pioneer Series Trust XIV) Pioneer ILS Bridge Fund Pioneer Multi-Asset Income Fund (a series of Pioneer Series Trust IV) Pioneer Real Estate Shares Pioneer Securitized Income Fund (a series of Pioneer Series Trust VI) Pioneer Short Term Income Fund Pioneer Strategic Income Fund (a series of Pioneer Series Trust XIV) Annex B Fund Class Fiscal Year End Regular Prospectus Date Expense Limit Expiration Pioneer Fundamental Growth Fund R 3/31 8/1 1.40 % 8/1/23 Amundi Climate Transition Core Bond Fund A 7/31 12/1 0.73 % 12/1/25 C 7/31 12/1 1.48 % 12/1/25 K 7/31 12/1 0.45 % 12/1/25 Y 7/31 12/1 0.45 % 12/1/25 Pioneer Balanced ESG Fund A 7/31 12/1 0.99 % 12/1/23 K 7/31 12/1 0.65 % 12/1/23 R 7/31 12/1 1.30 % 12/1/23 Y 7/31 12/1 0.65 % 12/1/23 Pioneer Multi-Asset Income Fund A 7/31 12/1 0.85 % 12/1/23 Y 7/31 12/1 0.65 % 12/1/23 Pioneer Securitized Income Fund A 7/31 12/1 0.90 % 12/1/23 C 7/31 12/1 1.65 % 12/1/23 K 7/31 12/1 0.65 % 12/1/23 Y 7/31 12/1 0.65 % 12/1/23 Pioneer Corporate High Yield Fund A 8/31 1/1 0.90 % 1/1/24 C 8/31 1/1 1.65 % 1/1/24 K 8/31 1/1 0.60 % 1/1/24 Y 8/31 1/1 0.60 % 1/1/24 Pioneer Disciplined Value Fund K 8/31 1/1 0.45 % 1/1/25 Y 8/31 1/1 0.45 % 1/1/25 Pioneer Global Sustainable Equity Fund (formerly, Pioneer Global Equity Fund) A 8/31 1/1 1.15 % 1/1/24 C 8/31 1/1 2.15 % 1/1/24 K 8/31 1/1 0.70 % 1/1/24 R 8/31 1/1 1.55 % 1/1/24 Y 8/31 1/1 0.70 % 1/1/24 Pioneer High Income Municipal Fund A 8/31 1/1 0.82 % 1/1/24 C 8/31 1/1 1.59 % 1/1/24 K 8/31 1/1 0.55 % 1/1/24 Y 8/31 1/1 0.55 % 1/1/24 Pioneer Short Term Income Fund A 8/31 1/1 0.83 % 1/1/24 K 8/31 1/1 0.46 % 1/1/24 Y 8/31 1/1 0.46 % 1/1/24 Pioneer Emerging Markets Equity Fund A 9/30 2/1 1.05 % 2/1/24 C 9/30 2/1 1.80 % 2/1/24 K 9/30 2/1 0.75 % 2/1/24 Y 9/30 2/1 0.75 % 2/1/24 Fund Class Fiscal Year End Regular Prospectus Date Expense Limit Expiration Pioneer Global Sustainable Growth Fund A 9/30 2/1 1.00 % 2/1/24 C 9/30 2/1 1.75 % 2/1/24 Y 9/30 2/1 0.70 % 2/1/24 Pioneer Global Sustainable Value Fund A 9/30 2/1 1.00 % 2/1/24 C 9/30 2/1 1.75 % 2/1/24 Y 9/30 2/1 0.70 % 2/1/24 Pioneer Intrinsic Value Fund A 9/30 2/1 0.85 % 2/1/24 C 9/30 2/1 1.60 % 2/1/24 Y 9/30 2/1 0.55 % 2/1/24 Pioneer Strategic Income Fund K 9/30 2/1 0.59 % 2/1/25 Y 9/30 2/1 0.69 % 2/1/25 Pioneer CAT Bond Fund A 10/31 3/1 1.75 % 3/1/24 K 10/31 3/1 1.50 % 3/1/24 Y 10/31 3/1 1.50 % 3/1/24 Pioneer Flexible Opportunities Fund* A 10/31 3/1 1.20 % 3/1/24 K 10/31 3/1 0.90 % 3/1/24 Y 10/31 3/1 0.90 % 3/1/24 Pioneer Floating Rate Fund A 10/31 3/1 1.05 % 3/1/24 Y 10/31 3/1 0.75 % 3/1/24 Pioneer Global High Yield Fund A 10/31 3/1 1.14 % 3/1/24 Y 10/31 3/1 0.90 % 3/1/24 Pioneer High Yield Fund A 10/31 3/1 1.10 % 3/1/24 Y 10/31 3/1 0.85 % 3/1/24 Pioneer ILS Bridge Fund N/A 10/31 3/1 1.99 % 3/1/24 Pioneer International Equity Fund A 11/30 4/1 1.15 % 4/1/24 C 11/30 4/1 2.15 % 4/1/24 K 11/30 4/1 0.70 % 4/1/24 Y 11/30 4/1 0.70 % 4/1/24 Pioneer AMT-Free Municipal Fund Y 12/31 5/1 0.49 % 5/1/25 Pioneer Fund K 12/31 5/1 0.61 % 5/1/24 Y 12/31 5/1 0.61 % 5/1/24 Pioneer Real Estate Shares A 12/31 5/1 1.50 % 5/1/24 Y 12/31 5/1 1.20 % 5/1/24 * Expense limitation applies to the fund’s direct ordinary operating expenses and not the expenses of the underlying funds.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!